Studyuncertain evidence
In noncardioembolic ischemic stroke or high-risk TIA, asundexian reduced ischemic stroke and did not increase major bleeding.
Annals of internal medicine·August 4, 2026·PMID 42546306
Why it mattersSecondary stroke prevention in noncardioembolic stroke remains challenging due to bleeding risks with current antithrombotics. A therapy that reduces ischemic events without increasing major bleeding would address a critical unmet need in vascular neurology and cardiology.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled